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The effect of Atlas-based automated segmentation (ABAS) on dose volume histogram (DVH) parameters
compared to manual segmentation (MS) in loco-regional radiotherapy (RT) of early breast cancer was
investigated in patients included in the Skagen Trial 1.
This analysis supports implementation of ABAS in clinical practice and multi-institutional trials.
 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Recently, an ESTRO delineation guideline-dependent atlas
based automated segmentation (ABAS) tool for radiation therapy
(RT) of early breast cancer using MIM Maestro software has been
developed and adopted at Aarhus University Hospital, Denmark
[1–3]. This ABAS tool has shown a significant reduction in segmen-
tation time and a high agreement against a gold standard manualsegmentation (MS), helping to overcome issues related to inter-
observer variability and workload burden of conventional manual
delineation [4]. Additionally, it maintained its reproducibility and
robustness in a multi-institutional clinical validation study [3].
The performance of ABAS against MS has been evaluated geomet-
rically using Dice Similarity Coefficient (DSC), Average Hausdorrf
Distance and difference in volume. However these geometric
parameters have limitations [5], and a more relevant dosimetric
analysis is needed to consolidate the contribution of this tool in
daily routine.
The purpose of this study was to assess if contouring variations
between ABAS and MS significantly affect dose parameters. In a
multi-institutional setting, the difference in dose coverage
between a manually corrected ABAS and MS of CTVs of the primary
(CTVp) and nodal (CTVn) volumes in patients eligible for loco-
regional RT of early breast cancer in the Skagen Trial 1 was
investigated.
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Patient selection
Approved treatment plans of 40 patients were selected from a
database of two previous studies investigating quality assurance
and ABAS within the Skagen Trial 1 [3]. Data were obtained from
7 institutions in Denmark, Belgium and Norway. To avoid bias
related to differences in target volumes or dose prescription, only
patients who received treatment of all nodal levels except L1, were
without boost administration or breast implants were allowed in
the study. Overall, 31 out of 40 treatment plans were also included
in the ABAS validation study [3], while the others were part of the
Skagen Trial 1 quality assurance protocol (Francolini et al., Quality
assessment of clinical target volume delineation and dose planning
in the clinically controlled randomized Skagen Trial 1, submitted to
radiotherapy and Oncology).
Gold standard manual segmentation (MS)
MS of breast (CTVp_breast), chest wall (CTVp_chest wall), nodal
levels except level I (CTVn) and internal mammary (CTVn_IMN)
was performed by multiple observers from the participating insti-
tutions according to the ESTRO consensus guideline for target vol-
ume delineation [1,2]. The immobilization, scanning and use of
breath adaptive technique followed the institutional procedures.
Atlas based automated segmentation and manual correction
ABAS was performed using four atlas libraries based on lateral-
ity and surgery, previously created on MIMMaestroTM software ver-
sion 6.5 (MIM Software Inc., Cleveland, OH) [3]. ABAS was exported
to the EclipseTM treatment planning system version 11.0.31 (Varian
Medical Systems Inc., Palo Alto, CA, USA) for revision and possible
manual correction according to the ESTRO delineation guideline.
Manual correction was performed by two research fellows (ARE
and GF), blind to the MS, and approved by a breast oncologist
(BVO).
Geometric comparison
Both MS and corrected ABAS (ABAScorrected) were exported to
the MIM software to calculate their spatial overlap (DSC) and vol-
umes for each of the segmented structures. The absolute difference
in volume (mL) was also calculated using the following Eq. (1):
DV ¼ jVðABASÞ  VðMSÞj ð1ÞTable 1
Baseline patients characteristic.
Patients’ characteristics Number
Surgery
Mastectomy 18
Lumpectomy 22
Laterality
Right 19
Left 21
Dose
40 Gy/15 fr 26
50 Gy/25 fr 14
Respiratory gating technique
Yes 33
No 7
Total 40Dosimetric comparison
For each patient, the dose plan used for treating the patient was
copied to the ABAScorrected structures. DVHs were created for both
MS and ABAS of CTVp, CTVn and CTVn_IMN. The DVH parameters
determined for both the MS and ABAScorrected dose plans included
the V90% (%) for CTVn and CTVn_IMN, the V95% (%) for CTVp either
breast or chest wall and the homogeneity index (HI), calculated
using the following Eq. (2) [6]:
HI ¼ ðD2% D98%Þ=D50%½6 ð2Þ
The absolute differences in these parameters between MS and
ABAScorrected were calculated using the following Eqs. (3–5):
DV90% ¼ jV90%ðABASÞ  V90%ðMSÞj ð3Þ
DV95% ¼ jV95%ðABASÞ  V95%ðMSÞj ð4ÞDHI ¼ jHIðABASÞ HIðMSÞj ð5Þ
V90% and V95% are expressed as a percentage of volume, thus,
DV95% and DV90% are also expressed as a percentage of volume.
Statistical analysis
Stata version 12.0 software (StataCorp., Texas, USA) was used
for statistical analysis. Descriptive statistics including median,
inter-quartile range (IQR) for all parameters were calculated. Sha-
piro–Wilk normality test showed that compared data did not fol-
low a normal distribution. So, a Wilcoxon signed rank test was
used to test the statistical significance of the difference in all
parameters and a Spearman’s rank correlation test was used for
correlation testing. Two sided p-values were provided and p-
values <0.05 were considered significant.
Results
Patients’ characteristics
Twenty patients included in the study were treated at Aarhus
University Hospital and the other 20 were treated at the other 6
institutions (Table 1).
Geometric difference
The median volume of ABAScorrected was larger than MS for
CTVp_breast and CTVn. CTVp_chest wall showed a larger median
volume of MS compared to the ABAScorrected. Both median MS
and ABAScorrected volumes were nearly the same for CTVn_IMN.
However, the difference was not significant for any of these vol-
umes. A high spatial overlap (median DSC P0.72) was seen
between MS and ABAScorrected for all compared structures.
CTVp_breast showed the best agreement followed by CTVp_chest
wall, CTVn and CTVn_IMN respectively (Table 2).
Dosimetric difference
Overall, HI comparison showed similar dose coverage for MS
and ABAScorrected; only CTVn and CTVn_IMN showed a minimal,
although statistically significant, difference for this parameter.
Fig. 1 shows examples of DVH for both MS and ABAScorrected
structures.
Both ABAScorrected and MS showed acceptable levels of coverage
on all target volumes. Differences were in favor of MS and were
statistically significant only for chest wall and CTVn_IMN, with
DV95% and DV90% of 2.5% and <1%, respectively (Table 2).
Table 2
Results of comparison between manual and automated segmentations as regard volume, DSC, HI, V95, and V90%.
Parameter CTVp-Breast (n = 22) CTVp-Chest wall (n = 18) CTVn-Total (n = 40) CTVn-IMN (n = 40)
Median (IQR) P-value Median (IQR) P-value Median (IQR) P-value Median (IQR) P-value
Volume (cc)
Manual 665.64 – 234.95 (220.22) – 52.39 (23.52) – 7.85 (3.12) –
ABAS (496.26) – 227.75 (160.34) – – 7.40 (1.88) –
DVolume 679.56 (427.42)
33 (56.41)
0.66 28.59 (36.90) 0.99 55.73 (19.13)
.90 (7.55)
0.21 0.95 (1.45) 0.96
DSC 0.93 (0.04) – 0.78 (0.06) – 0.76 (0.08) – 0.72 (0.10) –
HI
Manual 0.09 (0.06) – 0.10 (0.05) – 0.12 (0.04) – 0.13 (0.04) –
ABAS 0.09 (0.06) – 0.12 (0.10) – 0.12 (0.05) – 0.14 (0.05) –
D HI 0.01 (0.01) 0.49 0.02 (0.18) 0.23 0.01 (0.02) 0.01 0.01 (0.02) 0.002
CTVp V95% (%)
Manual 97.99 (5.57) – 97.25 (3.50) – – – – –
ABAS 98.38 (5.13) – 95.80 (3.27) – – – – –
D V95% 0.48 (0.74) 0.61 2.57 (2.74) 0.02 – – – –
CTVn V90% (%)
Manual – – – – 99.69 (1.28) – 96.13 (6.79) –
ABAS – – – – 99.48 (2.14) – 96.14 (10.51) –
D V90% – – – – 0.20 (1.05) 0.12 0.92 (3.42) 0.001
CTVp = clinical target volume of the primary tumor site, CTVn-Total = clinical target volume of the nodal levels 2,3,4 and inter-pectoral, CTVn-IMN = clinical target volume of
the internal mammary lymph nodes, cc = cubic centimeters, ABAS: Atlas-based automated segmentation, DSC = Dice Similarity Coefficient, HI = Homogeneity Index, V95%
= volume of the CTVp covered by 95% of the prescribed dose in percent, V90% = volume of the CTVn covered by 90% of the prescribed dose in percent, D = absolute difference,
SD = standard deviation, IQR = inter-quartile range.
Statistically significant P values are evidenced in bold in the table.
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No significant correlation was found between DSC values,DVol-
ume values or any of the DVH parameters used for CTVp_breast,
CTVp_chest wall and CTVn. A statistical significant correlation
between these different parameters was seen for CTVn_IMN. There
was a negative correlation between DSC and DHI or DV90%
(r = 0.60, p = 0.00 and 0.54, p = 0.0004, respectively) and a pos-
itive correlation between DVolume and DHI or DV90% (r = 0.40,
p = 0.01 and 0.50, p = 0,001, respectively). Finally, a negative signif-
icant correlation (r = 0.44, p = 0.004) was found between DSC and
DVolume for CTVn_IMN.Discussion
The results of the current study support that ABAS with manual
correction can be used safely for dose planning in loco-regional RT
of early breast cancer. A DSC >0.7 indicates low inter-observer vari-
ability [7], thus, median DSC values above 0.7 for all compared
CTVs in the current study reflected high agreement between MS
and ABAScorrected.
Results from the dosimetric comparison showed that dose cov-
erage for both CTVp and CTVn, corresponding to V95% and V90%,
respectively, were acceptable not only in clinical practice, but also
in the context of the Skagen Trial 1. Indeed, more than 95% of both
CTVp and CTVn ABAScorrected volumes were in median covered by
95% and 90% of prescribed dose, respectively. Furthermore, differ-
ences in these parameters were minimal, and only significant for
CTVp_chest wall. HI comparison demonstrated overlapping DVH
curves for ABAScorrected and MS (Fig. 1).
No significant differences were found for this parameter in
CTVp_breast or CTVp_chest wall reflecting a similar dose distribu-
tion for MS and ABAScorrected volumes. The median difference in HI
of CTVn between ABAScorrected and MS, even if statistically signifi-
cant, was only 0.01.
Thus, considering the optimal coverage levels for CTVn (V90%
> 99% for both ABAScorrected and MS) this difference was not clini-
cally relevant and under-dosage was not seen.In a population-based study, irradiation of IMN significantly
improves overall survival in node positive breast cancer patients
[8]. However, in left sided patients, balance against dose to the
heart and left anterior descending coronary artery is critical. In
the current study, a median 96% of CTVn_IMN volumes for both
ABAScorrected and MS were successfully covered by 90% of the pre-
scribed dose, and the median differences in V90% and HI between
ABAScorrected and MS for CTVn_IMN were minimal, although statis-
tically significant.
Results of a previous work have shown low contouring variabil-
ity between ABAScorrected and MS [3]. However, DSC reliability as an
absolute measure of delineation variability testing has been ques-
tioned, and geometric analysis used for this purpose may have lim-
its of performances [9]. Therefore, dosimetric comparison is
recommended to evaluate the performance of automated segmen-
tation in a more clinically relevant way [10]. Several studies have
looked at the difference in DVH parameters between MS and ABAS
in different tumor sites [11–16], and dosimetric analysis has been
used to quantify the clinical effect of inter-observer variability in
breast cancer RT [4,17]. One study has reported that inter-
observer variability is responsible for a significant variability in dose
coverage of the primary and nodal volumes among dose plans based
on nine observers’ contouring [4], with a difference in V95% ranging
between 10–25%. The current study has shown no significant differ-
ence in V95% between manual and automated segmentation of the
breast with an inter-quartile range of about 5% for both. Target cov-
erage was not influenced by the use of ABAScorrected or MS.
Another study has evaluated the performance of ABAS of the
breast in patients treated in prone position [17]. Results have
shown that a DSC >0.95 against MS has been correlated signifi-
cantly to better target dose coverage. Conversely, we cannot find
such correlation for the breast in the current study.
A significant correlation between variability in contouring and
dosimetric differences (DSC and DV) between MS and ABAScorrected
has been found for CTVn_IMN only. Therefore, a possible effect of
the amount of variation on the dose distribution within this small
structure will be expected and a minimal variation will ensure equal
coverage. However, the dosimetric difference is clinically acceptable
for both MS and ABAScorrected for CTVn_IMN in this study.
Fig. 1. Example of comparison between DVH curves measured in two patients on
ABAScorrected (blue dotted curve) and MS (red continue curve). DVHs are related to
chest wall (A) and breast (B) of a post-mastectomy and a post-lumpectomy patient.
CTV nodal (C) and CTVn_IMN (D) of a post-lumpectomy patient are represented in
the lower part of the figure. V95% and V90% are evidenced by the dotted line. On the
higher part of the graph is reported prescribed dose as an absolute value expressed
in Gy (50 Gy for A, 40 Gy for B, C and D). (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
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ABAScorrected are less than that reported in inter-observer variability
studies and within the range of clinical acceptance. Therefore, the
expected clinical outcome from routine use of ABAScorrected may be
considered equivalent to the use of conventional MS for dose plan-
ning in loco-regional RT of breast cancer with the advantage of less
time and inter-observer variability and more consistency and repro-
ducibility for ABAScorrected compared to MS.
Impact of ABAScorrected on organs at risk was not explored in this
analysis, however, it is reasonable to assume even a lower dosi-
metric impact on these structures.
A potential limitation of the methodology of the current study is
the use of the original dose plans based on the MS rather than gen-
erating specific plans for ABAScorrected. This may theoretically bias
the results. If the volume of the ABAScorrected is smaller than the
MS volume, it should be covered with the designed plans. How-
ever, structures with a comparable coverage level (CTVp_breast
and CTVn) between both segmentation methods have shown larger
median volumes of ABAScorrected, eliminating this bias. Moreover, a
better dosimetric coverage is expected if a new plan based on
ABAScorrected is created. Therefore, results of the current study
may represent the worst-case scenario.Conclusions
Data from this analysis confirmed the low contouring variability
between ABAS and MS.
Overall, comparison in HI and targets coverage showed that
dose distribution was similar regardless of the use of ABAS or
MS. Furthermore, no relationship was found between DSC and dif-
ferences in coverage, reflecting that performances of ABAS did not
affect dose parameters.
In the context of daily routine practice, ABAS could reduce the
time in RT workflow, without meaningful dosimetric impact on
treatment plan. This technique can be used in a multi-
institutional context. Thus, ABAS is a useful tool and its implemen-
tation in clinical activity should be considered.Conflict of Interest statement
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